Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort

被引：0
|
作者：
Servitja, Sonia
Torres, Elisabet
Prieto-Alhambra, Dani
Rodriguez-Sanz, Maria
Martinez-Garcia, Maria
Gonzalez Maeso, Iria
Diez-Perez, Adolf
Nogues, Xavi
Tusquets, Ignacio
机构：
[1] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
[2] Hosp del Mar, Dept Internal Med, URFOA, Barcelona, Spain
[3] Univ Oxford, Botnar Res Ctr, NDORMS, Oxford, England
[4] IMIM Parc Salut Mar, URFOA, Barcelona, Spain
[5] Hosp del Mar, Med Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
579
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss
    Hiscox, Stephen
    Barrett-Lee, Peter
    Borley, Annabel C.
    Nicholson, Robert I.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) : 2187 - 2195
  • [32] Weight Loss Exacerbates Bone Loss in Women on Aromatase Inhibitors: A Study of Breast Cancer Survivors
    Naaman, Sandra
    Vokes, Tamara
    Cursio, John
    Jain, Rajesh
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 213 - 213
  • [33] Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors
    Cepa, M.
    Vaz, C.
    ACTA REUMATOLOGICA PORTUGUESA, 2015, 40 (04): : 323 - 330
  • [34] Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women
    不详
    Drugs & Therapy Perspectives, 2009, 25 (10) : 23 - 26
  • [35] Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss
    Davis, S. R.
    Bell, R. J.
    Wang, Y.
    Hanna, F.
    Davies-Tuck, M.
    Bell, R.
    Chirgwin, J.
    Cicuttini, Flavia M.
    CLIMACTERIC, 2013, 16 (06) : 632 - 638
  • [36] Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment
    Josse, Robert G.
    CURRENT OPINION IN ONCOLOGY, 2007, 19 : S1 - S8
  • [37] PREDICTIVE FACTORS OF LONGITUDINAL BONE LOSS IN PATIENTS TREATED WITH AROMATASE INHIBITORS FOR BREAST CANCER
    Fowler, J.
    Mitchell, K.
    Bukhari, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 764 - 765
  • [38] Bone Loss Evaluation after One Year of Combined GnRH Agonist and Aromatase Inhibitors Therapy for Premenopausal Early Breast Cancers
    Nogues, Xavier
    Petit, Irene
    Servitja, Sonia
    Campodarve, Isabel
    Aymar, Isabel
    Pineda-Moncusi, Marta
    Ovejero, Diana
    Garcia-Giralt, Natalia
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 101 - 101
  • [39] FACTORS ASOCIATED WITH OSTEOPOROSIS AND BMD LOSS IN A COHORT OF WOMEN WITH BREAST CANCER TREATED WITH AROMATASE INHIBITORS
    Loarce-Martos, J.
    Sifuentes-Giraldo, W. A.
    Maldonado-Romero, L. V.
    Ahijon-Lana, M.
    Velazquez-Arce, C.
    Martinez-Janez, N.
    Vazquez-Diaz, M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S445 - S445
  • [40] Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
    Servitja, Sonia
    Nogues, Xavier
    Prieto-Alhambra, Daniel
    Martinez-Garcia, Maria
    Garrigos, Laia
    Jesus Pena, Maria
    de Ramon, Marta
    Diez-Perez, Adolfo
    Albanell, Joan
    Tusquets, Ignasi
    BREAST, 2012, 21 (01): : 95 - 101
12345